These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 19008797)

  • 1. [Effects of the anticholinesterase drug neuromidin in patients with schizophrenia with marked neurocognitive deficits].
    Morozova MA; Beniashvili AG; Rupchev GE; Lepilkina TA; Starostin DS; Brusov OS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(11):28-35. PubMed ID: 19008797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind placebo-controlled randomized efficacy and safety trial of add-on treatment of dimebon plus risperidone in schizophrenic patients during transition from acute psychotic episode to remission.
    Morozova MA; Beniashvili AG; Lepilkina TA; Rupchev GE
    Psychiatr Danub; 2012 Jun; 24(2):159-66. PubMed ID: 22706414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The use of neuromidin in patients with minor ischemic stroke].
    Maksimova MIu; Sharov MN; Sineva NA; Vodop'ianov NP
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(8 Pt 2):35-40. PubMed ID: 22224243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
    Sharma T; Reed C; Aasen I; Kumari V
    Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia.
    Matsuda Y; Sato S; Iwata K; Furukawa S; Hatsuse N; Watanabe Y; Anzai N; Kishimoto T; Ikebuchi E
    Psychiatry Clin Neurosci; 2014 Jun; 68(6):425-31. PubMed ID: 24506576
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia.
    Lindenmayer JP; Khan A
    Schizophr Res; 2011 Feb; 125(2-3):267-77. PubMed ID: 20850275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study.
    Morozova MA; Lepilkina TA; Rupchev GE; Beniashvily AG; Burminskiy DS; Potanin SS; Bondarenko EV; Kazey VI; Lavrovsky Y; Ivachtchenko AV
    CNS Spectr; 2014 Aug; 19(4):316-23. PubMed ID: 23768250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial.
    Suzuki H; Gen K; Inoue Y; Hibino H; Mikami A; Matsumoto H; Mikami K
    Int J Psychiatry Clin Pract; 2014 Jan; 18(1):58-62. PubMed ID: 24047427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of neuroleptic treatments on executive function and symptomatology in schizophrenia: a 1-year follow up study.
    Rémillard S; Pourcher E; Cohen H
    Schizophr Res; 2005 Dec; 80(1):99-106. PubMed ID: 16162401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cognitive disorders in the early rehabilitation period of ischemic stroke and possibilities of their treatment with neuromidin].
    Pustokhanova LV; Morozova EM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2011; 111(4 Pt 2):23-7. PubMed ID: 23120773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationship of neuropsychological test performance with the PANSS in antipsychotic naïve, first-episode psychosis patients.
    Good KP; Rabinowitz J; Whitehorn D; Harvey PD; DeSmedt G; Kopala LC
    Schizophr Res; 2004 May; 68(1):11-9. PubMed ID: 15037335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits.
    Chouinard S; Stip E; Poulin J; Melun JP; Godbout R; Guillem F; Cohen H
    Curr Med Res Opin; 2007 Mar; 23(3):575-83. PubMed ID: 17355738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of anticholinergic load with impairment of complex attention and memory in schizophrenia.
    Minzenberg MJ; Poole JH; Benton C; Vinogradov S
    Am J Psychiatry; 2004 Jan; 161(1):116-24. PubMed ID: 14702259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
    Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis.
    Citrome L; Meng X; Hochfeld M
    Schizophr Res; 2011 Sep; 131(1-3):75-81. PubMed ID: 21700430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized crossover study of the histamine H3 inverse agonist MK-0249 for the treatment of cognitive impairment in patients with schizophrenia.
    F Egan M; Zhao X; Gottwald R; Harper-Mozley L; Zhang Y; Snavely D; Lines C; Michelson D
    Schizophr Res; 2013 May; 146(1-3):224-30. PubMed ID: 23523692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.